US pharmacy chain settles Medicaid fraud allegations
This article was originally published in Scrip
The US pharmacy chain Walgreens has paid the US government and four states $9.9 million to resolve allegations it submitted false billings under Medicaid's low-income health programme, the US Justice Department said. The department's civil division alleged that Walgreens submitted claims to Medicaid agencies in the four states for prescription drugs for people covered by both Medicaid and by private third-party insurance. It then allegedly charged the states for the difference between what the private insurers paid and what the state programmes would have paid in the absence of private insurance. The government further alleges that: "The claims were false because the drug chain was entitled to reimbursement from the Medicaid programmes only for the amount the Medicaid beneficiary would have been obligated to pay Walgreens had the claims been submitted solely to the private insurers, typically the co-payment amount, yet it knowingly submitted claims to the Medicaid programmes in excess of the co-pay amount."
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.